Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for Transplantation

This study is testing whether a low dose of cyclophosphamide (a chemotherapy drug, abbreviated CTX) can work as ongoing maintenance therapy for people with multiple myeloma (a blood cancer affecting plasma cells) who are not candidates for stem cell transplant and who achieved a very good response to initial treatment. **You may be eligible if:** - You have multiple myeloma that is secretory (produces measurable proteins in the blood or urine) - You are 18 years or older - You completed induction and consolidation therapy (8 courses of chemotherapy) and achieved at least a very good partial response (VGPR) - You were not suitable for stem cell transplant - Your heart and lung function are adequate (grade I or below) - Your overall performance score (KPS) is at least 70% **You may NOT be eligible if:** - You have high cytogenetic risk features (specific chromosome changes that make the cancer more aggressive) - Your myeloma has relapsed or become refractory - You underwent autologous stem cell transplant as consolidation - You did not achieve at least a VGPR response before enrollment - Your cancer is asymptomatic (smoldering myeloma) Talk to your doctor to see if this trial is right for you.